CD274 and melanoma: In addition, “real world” clinical evidence derived from case reports and retrospective clinical analysis of patients with advanced melanoma shows that the simultaneous inhibition of RANKL and PD-L1 promotes the efficacy of immune checkpoint inhibitors (Liede et al., 2018).